Your browser doesn't support javascript.
loading
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
van Dam, Koos P J; Volkers, Adriaan G; Wieske, Luuk; Stalman, Eileen W; Kummer, Laura Y L; van Kempen, Zoé L E; Killestein, Joep; Tas, Sander W; Boekel, Laura; Wolbink, Gerrit J; van der Kooi, Anneke J; Raaphorst, Joost; Takkenberg, R Bart; D'Haens, Geert R A M; Spuls, Phyllis I; Bekkenk, Marcel W; Musters, Annelie H; Post, Nicoline F; Bosma, Angela L; Hilhorst, Marc L; Vegting, Yosta; Bemelman, Frederike J; Voskuyl, Alexandre E; Broens, Bo; Sanchez, Agner Parra; van Els, Cécile A C M; de Wit, Jelle; Rutgers, Abraham; de Leeuw, Karina; Horváth, Barbara; Verschuuren, Jan J G M; Ruiter, Annabel M; van Ouwerkerk, Lotte; van der Woude, Diane; Allaart, Renée C F; Teng, Y K Onno; van Paassen, Pieter; Busch, Matthias H; Jallah, Papay B P; Brusse, Esther; van Doorn, Pieter A; Baars, Adája E; Hijnen, Dirk Jan; Schreurs, Corine R G; van der Pol, W Ludo; Goedee, H Stephan; Steenhuis, Maurice; Keijzer, Sofie; Keijser, Jim B D; Cristianawati, Olvi.
Afiliação
  • van Dam KPJ; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • Volkers AG; Department of Gastroenterology and Hepatology, Location Academic Medical Center, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Wieske L; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • Stalman EW; Department of Clinical Neurophysiology, St Antonius Hospital, Nieuwegein, The Netherlands.
  • Kummer LYL; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • van Kempen ZLE; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • Killestein J; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands.
  • Tas SW; Department of Neurology, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.
  • Boekel L; Department of Neurology, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.
  • Wolbink GJ; Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam, the Netherlands.
  • van der Kooi AJ; Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Amsterdam, the Netherlands.
  • Raaphorst J; Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Amsterdam, the Netherlands.
  • Takkenberg RB; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • D'Haens GRAM; Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
  • Spuls PI; Department of Gastroenterology and Hepatology, Location Academic Medical Center, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Bekkenk MW; Department of Gastroenterology and Hepatology, Location Academic Medical Center, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Musters AH; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Post NF; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Bosma AL; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Hilhorst ML; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Vegting Y; Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Bemelman FJ; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Voskuyl AE; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Broens B; Department of Internal Medicine, Section of Nephrology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Sanchez AP; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands.
  • van Els CACM; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands.
  • de Wit J; Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam, the Netherlands.
  • Rutgers A; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands.
  • de Leeuw K; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
  • Horváth B; Faculty of Veterinary Medicine, Utrecht University Utrecht, Utrecht, The Netherlands.
  • Verschuuren JJGM; Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
  • Ruiter AM; Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands.
  • van Ouwerkerk L; Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands.
  • van der Woude D; Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University Groningen, Groningen, The Netherlands.
  • Allaart RCF; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
  • Teng YKO; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
  • van Paassen P; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Busch MH; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Jallah PBP; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Brusse E; Centre of Expertise for Lupus-, Vasculitis- and Complement-Mediated Systemic Diseases, Department of Internal Medicine - Nephrology section, Leiden University Medical Centre, Leiden, The Netherlands.
  • van Doorn PA; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Baars AE; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Hijnen DJ; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Schreurs CRG; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • van der Pol WL; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Goedee HS; Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Steenhuis M; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Keijzer S; Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
  • Keijser JBD; Department of Neurology and Neurosurgery, Brain Center UMC Utrecht, Utrecht, the Netherlands.
  • Cristianawati O; Department of Neurology and Neurosurgery, Brain Center UMC Utrecht, Utrecht, the Netherlands.
BMC Infect Dis ; 23(1): 332, 2023 May 17.
Article em En | MEDLINE | ID: mdl-37198536
BACKGROUND: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term humoral immune responses against SARS-CoV-2 and increased disease activity after a primary SARS-CoV-2 infection in unvaccinated IMID patients on ISPs. METHODS: IMID patients on active treatment with ISPs and controls (i.e. IMID patients not on ISP and healthy controls) with a confirmed SARS-CoV-2 infection before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical data on infections and increased disease activity were registered using electronic surveys and health records. A serum sample was collected before first vaccination to measure SARS-CoV-2 anti-receptor-binding domain (RBD) antibodies. RESULTS: In total, 193 IMID patients on ISP and 113 controls were included. Serum samples from 185 participants were available, with a median time of 173 days between infection and sample collection. The rate of seropositive IMID patients on ISPs was 78% compared to 100% in controls (p < 0.001). Seropositivity rates were lowest in patients on anti-CD20 (40.0%) and anti-tumor necrosis factor (TNF) agents (60.5%), as compared to other ISPs (p < 0.001 and p < 0.001, respectively). Increased disease activity after infection was reported by 68 of 260 patients (26.2%; 95% CI 21.2-31.8%), leading to ISP intensification in 6 out of these 68 patients (8.8%). CONCLUSION: IMID patients using ISPs showed reduced long-term humoral immune responses after primary SARS-CoV-2 infection, which was mainly attributed to treatment with anti-CD20 and anti-TNF agents. Increased disease activity after SARS-CoV-2 infection was reported commonly, but was mostly mild. TRIAL REGISTRATION: NL74974.018.20, Trial ID: NL8900. Registered on 9 September 2020.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article